Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2020

September 2020 | 386 pages | ID: HA9B63A4DA9EN
Global Markets Direct

Abstracts

Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2020, provides an overview of the Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline landscape.
Human papillomavirus (HPV) is the most common viral infection of the reproductive tract. Human papillomavirus (HPV) has been found to be associated with several types of cancer. Risk factors include smoking, weakened immune system, long-term oral contraceptive use and chronic inflammation. Human papillomavirus (HPV) associated cancer have no symptoms until it is quite advanced, very serious and hard to treat.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Human Papillomavirus (HPV) Associated Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Human Papillomavirus (HPV) Associated Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 26, 15, 33, 6 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 1, 12 and 2 molecules, respectively.
Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:
Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Human Papillomavirus (HPV) Associated Cancer (Oncology).
• The pipeline guide reviews pipeline therapeutics for Human Papillomavirus (HPV) Associated Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Human Papillomavirus (HPV) Associated Cancer (Oncology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Human Papillomavirus (HPV) Associated Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Human Papillomavirus (HPV) Associated Cancer (Oncology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Human Papillomavirus (HPV) Associated Cancer (Oncology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Human Papillomavirus (HPV) Associated Cancer - Overview
Human Papillomavirus (HPV) Associated Cancer - Therapeutics Development
Human Papillomavirus (HPV) Associated Cancer - Therapeutics Assessment
Human Papillomavirus (HPV) Associated Cancer - Companies Involved in Therapeutics Development
Human Papillomavirus (HPV) Associated Cancer - Drug Profiles
Human Papillomavirus (HPV) Associated Cancer - Dormant Projects
Human Papillomavirus (HPV) Associated Cancer - Discontinued Products
Human Papillomavirus (HPV) Associated Cancer - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Human Papillomavirus (HPV) Associated Cancer, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Abion Inc, H2 2020
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Abivax SA, H2 2020
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Advaxis Inc, H2 2020
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Anteris Technologies Ltd, H2 2020
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Antiva Biosciences Inc, H2 2020
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Apimeds Inc, H2 2020
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2020
Human Papillomavirus (HPV) Associated Cancer - Pipeline by AstraZeneca Plc, H2 2020
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Atara Biotherapeutics Inc, H2 2020
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Avalia Immunotherapies Ltd, H2 2020
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Beijing Recreation Guards Biotechnology Co Ltd, H2 2020
Human Papillomavirus (HPV) Associated Cancer - Pipeline by BioMed Valley Discoveries Inc, H2 2020
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Biond Biologics Ltd, H2 2020
Human Papillomavirus (HPV) Associated Cancer - Pipeline by BioNTech SE, H2 2020
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Blue Sky Immunotherapies GmbH, H2 2020
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Cellid Co Ltd, H2 2020
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Chain Biotechnology Ltd, H2 2020
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Chengdu Institute of Biological Products Co Ltd, H2 2020
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Cue Biopharma Inc, H2 2020
Human Papillomavirus (HPV) Associated Cancer - Dormant Projects, H2 2020
Human Papillomavirus (HPV) Associated Cancer - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Human Papillomavirus (HPV) Associated Cancer, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020

COMPANIES MENTIONED

Abion Inc
Abivax SA
Advaxis Inc
Anteris Technologies Ltd
Antiva Biosciences Inc
Apimeds Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Atara Biotherapeutics Inc
Avalia Immunotherapies Ltd
Beijing Recreation Guards Biotechnology Co Ltd
BioMed Valley Discoveries Inc
Biond Biologics Ltd
BioNTech SE
Blue Sky Immunotherapies GmbH
Cellid Co Ltd
Chain Biotechnology Ltd
Chengdu Institute of Biological Products Co Ltd
Cue Biopharma Inc
Cullinan Oncology LLC
Elicio Therapeutics
Etubics Corp
EyeGene Inc
Genexine Inc
Gilead Sciences Inc
Hookipa Pharma Inc
iBio Inc
Immunomic Therapeutics Inc
IMV Inc
Innovene
Inovio Pharmaceuticals Inc
Inthera Bioscience AG
Iovance Biotherapeutics Inc
ISA Pharmaceuticals BV
Ispin Inc
Johnson & Johnson
Juno Therapeutics Inc
Merck KGaA
OncoNano Medicine Inc
Onconova Therapeutics Inc
Oxford Vacmedix UK Ltd
Papivax LLC
Pathovax LLC
Pattern Pharma Inc
PDS Biotechnology Corp
Precigen Inc
Privo Technologies Inc
Profectus BioSciences Inc
Rottapharm Biotech Srl
Rubius Therapeutics Inc
Shanghai Bovax Biotechnology Co Ltd
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shantha Biotechnics Pvt Ltd
Shuttle Pharmaceuticals Inc
TCR Cure Biopharma Technology Co Ltd
Theravectys SA
THEVAX Genetics Vaccine USA Inc
Touchlight Genetics Ltd
Transgene SA
Turnstone Biologics Inc
UbiVac LLC
Vaccibody AS
Vault Pharma Inc
Vectorite Biomedical Inc
ViciniVax BV
Vir Biotechnology Inc
Virion Therapeutics LLC
Virometix AG
VLP The Vaccines Company SL
Voltron Therapeutics Inc
Xiamen Innovax Biotech Co Ltd